Xilio Therapeutics (XLO) Stock Statistics & Valuation Metrics

Xilio Therapeutics has a market cap or net worth of $60.16M. The enterprise value is -$86.16M.

Xilio Therapeutics has 6,575,139 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xilio Therapeutics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -42.09%.

The current PE Ratio of Xilio Therapeutics is ―. Xilio Therapeutics’s PEG ratio is 0.03.

In the last 12 months, Xilio Therapeutics had revenue of 43.77M and earned -35.04M in profits. Earnings per share was -4.19.

In the last 12 months, operating cash flow was -56.31M and capital expenditures -1.05M, giving a free cash flow of -57.37M billion.

Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Xilio Therapeutics upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).

Xilio Therapeutics as a current ratio of 2.58, with Debt / Equity ratio of 9.15%

In the past 12 months, Xilio Therapeutics has paid 0.00 in taxes.

Xilio Therapeutics EV to EBITDA ratio is -18.46, with an EV/FCF ratio of -112.23.

Xilio Therapeutics has $150.33M in cash and marketable securities with $6.64M in debt, giving a net cash position of $143.69M billion.

Gross margin is 70.69%, with operating margin of -95.92%, and net profit margin of -80.05%.

The average price target for Xilio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―